Cyramza (ramucirumab) vs Lumakras (sotorasib)

Cyramza (ramucirumab) is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), which can inhibit the growth of blood vessels that supply tumors, and is commonly used to treat certain types of lung, gastric, and colorectal cancers. Lumakras (sotorasib) is a small molecule inhibitor specifically designed to target the KRAS G12C mutation, a common mutation in non-small cell lung cancer (NSCLC), and is indicated for patients with this specific genetic marker. The choice between Cyramza and Lumakras would largely depend on the genetic profile of the cancer, the type and stage of the cancer, and the patient’s overall health and treatment history, making it crucial for a patient to discuss with their oncologist to determine the most appropriate treatment based on their individual condition.

Difference between Cyramza and Lumakras

Metric	Cyramza (ramucirumab)	Lumakras (sotorasib)
Generic name	ramucirumab	sotorasib
Indications	Gastric cancer, non-small cell lung cancer, colorectal cancer, hepatocellular carcinoma	Non-small cell lung cancer (NSCLC) with KRAS G12C mutation
Mechanism of action	Angiogenesis inhibitor by VEGFR-2 antagonism	KRAS G12C inhibitor
Brand names	Cyramza	Lumakras
Administrative route	Intravenous infusion	Oral
Side effects	Hypertension, diarrhea, headache, hyponatremia	Diarrhea, hepatotoxicity, cough, dyspnea, musculoskeletal pain
Contraindications	Hypersensitivity to ramucirumab or any excipients	Hypersensitivity to sotorasib or any excipients
Drug class	Monoclonal antibody	Small molecule kinase inhibitor
Manufacturer	Eli Lilly and Company	Amgen Inc.

Efficacy

Efficacy of Cyramza (Ramucirumab) in Lung Cancer

Cyramza (ramucirumab) is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), which is involved in the growth of blood vessels that supply tumors with nutrients and oxygen. In the context of lung cancer, Cyramza has been shown to be effective when used in combination with docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. Clinical trials have demonstrated that this combination extends overall survival compared to docetaxel alone, offering an additional option for patients with this type of advanced lung cancer.

The efficacy of Cyramza was evaluated in a pivotal phase III trial known as REVEL. In this study, patients receiving Cyramza plus docetaxel had a median overall survival of 10.5 months compared to 9.1 months for those receiving docetaxel alone. Progression-free survival was also improved, albeit modestly, with the combination therapy. These results support the use of Cyramza in combination with docetaxel for the second-line treatment of patients with metastatic NSCLC.

Efficacy of Lumakras (Sotorasib) in Lung Cancer

Lumakras (sotorasib) is a novel medication specifically designed to target the KRAS G12C mutation, which is a genetic alteration found in a subset of NSCLC tumors. Sotorasib represents a significant advancement in the treatment of lung cancer, as it is the first therapy approved that directly inhibits the KRAS G12C mutation. The efficacy of Lumakras has been demonstrated in clinical trials for patients with NSCLC who harbor the KRAS G12C mutation and have received at least one prior systemic therapy.

In a phase II trial known as CodeBreaK 100, Lumakras showed promising results, with a confirmed objective response rate of approximately 37% in patients with previously treated KRAS G12C-mutated NSCLC. The median duration of response was 10 months, indicating that Lumakras can provide a meaningful clinical benefit in this patient population. The drug's approval offers a targeted treatment option for patients with this specific genetic profile, addressing a previously unmet need in the management of NSCLC.

Regulatory Agency Approvals

Cyramza

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Lumakras

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Medicines & Healthcare products Regulatory Agency (MHRA), United Kingdom

Access Cyramza or Lumakras today

If Cyramza or Lumakras are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Cyramza

Buy Lumakras

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: